Behavioral Health Innovation Center
The Vail Health Behavioral Health Innovation Center resembles academic medical centers and research universities. Collaborating with researchers at the University of Wisconsin–Madison on initial studies focused on basic science and preclinical investigations, future collaborations are envisioned with other institutions.
Upcoming Lectures
Session 10 | April 4, 2024 | 12:00 - 1:00PM MST | ZOOM (Online)
Keeping the Psychedelic Renaissance from Going Off the Rails
Presented by Andrew Penn, MS, PMHNP and Charles L. Raison, MD
Some psychedelic-assisted therapies, such as MDMA for post-traumatic stress disorder and psilocybin for major depression, are either approaching the end of clinical trials or are amid clinical trials that may soon lead to FDA approval. A prescribed combination of drug plus therapy is new territory for clinicians, regulators, and patients. Because of this, the question of how these combined therapies will be administered remains an open one of some urgency.
Andrew Penn, MS, PMHN, and Charles Raison, MD will explore the implications, opportunities, and challenges of this change in how we treat mental illness from the perspective of multiple stakeholders
REGISTER TO WATCH > REGISTER FOR CREDIT >
Lecture Series
LEARN MORE > HOW TO REGISTER > ALL UPCOMING LECTURES >
Past Lectures
Studies
- CHILL'D Study (“Cold and Heat Investigation to Lower Levels of Depression”) will explore ways to optimize the proven benefits of hyperthermia for depression, including whether adding cold to heat will improve outcomes and whether hyperthermia can be effectively combined with standard antidepressants.
- The RECAP Follow-Up Study, which will be conducted at UW–Madison, will use model systems to develop and optimize neuroscience techniques for assessing the effects of psilocybin on the brain in context of mental health disorders. Results of this work will inform the subsequent OPT-IN Study.
- The OPT-IN Study (Optimizing Psilocybin), which will be conducted at Vail Health BHIC, will examine novel ways to enhance the impact of psilocybin on depression and anxiety via co-administration of non-invasive vagus nerve stimulation. It will also assess the impact of psilocybin on real-world social behavior and will use advanced strategies to better understand the risks and benefits of psilocybin use in a legalized setting, such as Colorado.